Chemokine CXCL10 at Week 4 of Treatment Predicts Sustained Virological Response in Patients with Chronic Hepatitis C

Kurelac, Ivan; Židovec Lepej, Snježana; Grgić, Ivana; Gorenec, Lana; Papić, Neven; Dušek, Davorka; Baršić, Bruno; Vince, Adriana

doi:10.1089/jir.2012.0006

Pregled bibliografske jedinice broj: 599309

Chemokine CXCL10 at Week 4 of Treatment Predicts Sustained Virological Response in Patients with Chronic Hepatitis C

Kurelac, Ivan; Židovec Lepej, Snježana; Grgić, Ivana; Gorenec, Lana; Papić, Neven; Dušek, Davorka; Baršić, Bruno; Vince, Adriana

Chemokine CXCL10 at Week 4 of Treatment Predicts Sustained Virological Response in Patients with Chronic Hepatitis C // Journal of interferon & cytokine research, 32 (2012), 8; 386-391 doi:10.1089/jir.2012.0006 (međunarodna recenzija, članak, znanstveni)

CROSBI ID: 599309 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Chemokine CXCL10 at Week 4 of Treatment Predicts Sustained Virological Response in Patients with Chronic Hepatitis C

Autori
Kurelac, Ivan ; Židovec Lepej, Snježana ; Grgić, Ivana ; Gorenec, Lana ; Papić, Neven ; Dušek, Davorka ; Baršić, Bruno ; Vince, Adriana

Izvornik
Journal of interferon & cytokine research (1079-9907) 32 (2012), 8; 386-391

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
CXCL10 ; CXCL11 ; CXCL9 ; HCV ; SVR ; interferon

Sažetak
The aim of this study was to analyze the predictive value of CXCL9, CXCL10, and CXCL11 concentrations before and after 4 and 12 weeks of treatment with pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C infected with the hepatitis C virus genotype 1. The study included 46 adult patients (29 women and 17 men). Chemokine quantification in the serum was performed at baseline and after 1, 3, and 6 months of treatment by enzyme immunoassay. Chemokine responses were compared in patients achieving a sustained virological response to treatment (SVR, n=26) and the non-SVR group (n=20). The differences in the CXCL9 and CXCL10 concentrations between the SVR and non-SVR groups were statistically significant. A multivariant analysis showed a significant association between treatment failure and higher concentrations of CXCL10. A higher predictive value of CXCL10 concentrations after 4 weeks of treatment compared to pretreatment values has been found (area under the curve 0.9288 and 0.7942, respectively, P=0.016). CXCL10 concentrations above 250 pg/mL 4 weeks after the start of treatment were independently associated with non-SVR. In conclusion, the results of this study have shown that CXCL10 concentrations at the time of a rapid viral response (4 weeks) are better predictors of achieving SVR compared to baseline levels. Additionally, this study suggests an important role of CXCL9 as a biomarker of SVR in patients with chronic hepatitis C.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA

Projekti:
MZOS-143-0000000-0117 - Imunopatogeneza hepatitisa B i C (Vince, Adriana, MZOS ) ( CroRIS)
MZOS-143-1080116-0097 - Imunološka rekonstitucija i rezistencija na lijekove u HIV-bolesnika iz Hrvatske (Židovec-Lepej, Snježana, MZOS ) ( CroRIS)

Ustanove:
Klinika za infektivne bolesti "Dr Fran Mihaljević"

Profili:

Ivana Grgić (autor)